Phathom Pharmaceuticals Inc (PHAT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $492.63M
Last updated: Nov 17, 2026 at 11:05 AM ET
Phathom Pharmaceuticals Inc (PHAT) Earnings: Report Dates and Results
Phathom Pharmaceuticals (PHAT) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Phathom Pharmaceuticals reported EPS of -$0.03, below the -$0.01 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PHAT has an expected report date of Feb 24, 2027.
PHAT Earnings Call
The latest PHAT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 29 quarters below that had an estimate, PHAT beat 16 and missed 13. Revenue for the quarter ended Sep 30, 2026 was $84.72M, up 71.2% from $49.50M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.03 | -$0.01 | -$0.02 - $0.07 | -200.00% | Miss | N/A | 5 | 0 up, 2 down | Oct 29, 2026 | $84.72M |
| Jun 30, 2026 | -$0.08 | -$0.15 | N/A | +46.67% | Beat | N/A | 4 | 0 up, 3 down | Jul 30, 2026 | $74.27M |
| Mar 31, 2026 | -$0.18 | -$0.39 | N/A | +53.81% | Beat | N/A | 4 | 1 up, 1 down | Apr 30, 2026 | $58.30M |
| Dec 31, 2025 | -$0.16 | -$0.20 | -$0.42 - -$0.09 | +20.00% | Beat | N/A | 5 | 1 up, 1 down | Feb 26, 2026 | $57.58M |
| Sep 30, 2025 | -$0.15 | -$0.41 | -$0.59 - -$0.30 | +63.41% | Beat | N/A | 4 | 1 up, 0 down | Oct 30, 2025 | $49.50M |
| Jun 30, 2025 | -$0.90 | -$0.86 | -$1.11 - -$0.64 | -4.65% | Miss | N/A | 4 | 0 up, 1 down | Aug 7, 2025 | $39.50M |
| Mar 31, 2025 | -$1.07 | -$1.07 | -$1.13 - -$1.03 | -0.38% | Miss | N/A | 5 | 1 up, 1 down | May 1, 2025 | $28.52M |
| Dec 31, 2024 | -$1.05 | -$1.08 | -$1.17 - -$0.98 | +2.78% | Beat | N/A | 4 | 0 up, 1 down | Mar 6, 2025 | $29.66M |
| Sep 30, 2024 | -$1.05 | -$1.46 | -$1.74 - -$1.22 | +28.08% | Beat | N/A | 6 | 0 up, 0 down | Nov 7, 2024 | $16.35M |
| Jun 30, 2024 | -$1.25 | -$1.24 | N/A | -0.81% | Miss | N/A | 6 | 1 up, 0 down | Aug 8, 2024 | $7.32M |
| Mar 31, 2024 | -$1.11 | -$1.22 | -$1.76 - -$1.01 | +9.02% | Beat | N/A | 8 | 0 up, 1 down | May 9, 2024 | $1.91M |
| Dec 31, 2023 | -$1.39 | -$1.08 | -$1.52 - -$0.85 | -28.70% | Miss | N/A | 7 | 0 up, 0 down | Mar 7, 2024 | $682000 |
| Sep 30, 2023 | -$0.76 | -$0.96 | -$1.11 - -$0.65 | +20.83% | Beat | N/A | 7 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.84 | -$0.95 | -$1.25 - -$0.78 | +11.58% | Beat | N/A | 7 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.89 | -$1.28 | -$1.37 - -$1.06 | +30.47% | Beat | N/A | 6 | 0 up, 0 down | May 10, 2023 | N/A |
| Dec 31, 2022 | -$1.33 | -$1.35 | -$1.50 - -$1.23 | +1.48% | Beat | N/A | 6 | 0 up, 0 down | Feb 28, 2023 | N/A |
| Sep 30, 2022 | -$1.32 | -$1.33 | -$1.46 - -$1.25 | +0.75% | Beat | N/A | 6 | 0 up, 0 down | Nov 8, 2022 | N/A |
| Jun 30, 2022 | -$1.33 | -$1.11 | -$1.14 - -$0.81 | -19.82% | Miss | N/A | 4 | 0 up, 1 down | Aug 2, 2022 | N/A |
| Mar 31, 2022 | -$1.07 | -$1.02 | -$1.10 - -$0.90 | -4.90% | Miss | N/A | 5 | 0 up, 0 down | May 10, 2022 | N/A |
| Dec 31, 2021 | -$0.95 | -$1.03 | -$1.24 - -$0.86 | +7.77% | Beat | N/A | 6 | N/A | Mar 1, 2022 | N/A |
| Sep 30, 2021 | -$0.98 | -$1.03 | -$1.09 - -$0.88 | +4.85% | Beat | N/A | 6 | 3 up, 1 down | Nov 8, 2021 | N/A |
| Jun 30, 2021 | -$1.00 | -$0.99 | -$1.18 - -$0.99 | -1.01% | Miss | N/A | 6 | N/A | Aug 10, 2021 | N/A |
| Mar 31, 2021 | -$0.96 | -$1.19 | -$1.40 - -$0.94 | +19.33% | Beat | N/A | 6 | N/A | May 11, 2021 | N/A |
| Dec 31, 2020 | -$1.58 | -$1.12 | -$1.23 - -$0.90 | -41.07% | Miss | N/A | 6 | N/A | Mar 30, 2021 | N/A |
| Sep 30, 2020 | -$1.02 | -$0.67 | -$0.68 - -$0.66 | -52.24% | Miss | N/A | 3 | N/A | Nov 10, 2020 | N/A |
| Jun 30, 2020 | -$0.64 | -$0.62 | N/A | -3.23% | Miss | N/A | 2 | N/A | Aug 6, 2020 | N/A |
| Mar 31, 2020 | -$0.62 | -$0.72 | -$0.81 - -$0.59 | +13.89% | Beat | N/A | 3 | N/A | May 12, 2020 | N/A |
| Dec 31, 2019 | -$3.97 | -$1.25 | -$2.28 - -$0.65 | -217.60% | Miss | N/A | 3 | N/A | Mar 19, 2020 | N/A |
| Sep 30, 2019 | -$3.72 | -$3.02 | N/A | -23.18% | Miss | N/A | 2 | N/A | Oct 28, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.28, after -$4.46 the year before. It was -$7.69 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.28 | N/A |
| Dec 31, 2024 | -$4.46 | N/A |
| Dec 31, 2023 | -$3.88 | N/A |
| Dec 31, 2022 | -$5.05 | N/A |
| Dec 31, 2021 | -$3.89 | N/A |
| Dec 31, 2020 | -$3.86 | N/A |
| Dec 31, 2019 | -$7.69 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 10,000 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 10,138 | 15 | |
| 2026Q2 | Jun 30, 2026 | 6,079 | 14 | |
| 2026Q1 | Mar 31, 2026 | 7,844 | 14 | |
| 2025Q4 | Dec 31, 2025 | 7,123 | 13 | |
| 2025Q3 | Sep 30, 2025 | 8,780 | 13 | |
| 2025Q2 | Jun 30, 2025 | 4,937 | 11 | |
| 2025Q1 | Mar 31, 2025 | 8,091 | 11 | |
| 2024Q4 | Dec 31, 2024 | 6,404 | 12 |
2026Q3 Earnings Call
Opening remarks
Eric Sciorilli Head of Investor Relations Thank you, operator. Hello everyone, and thank you for joining us this morning to discuss Phathom's third quarter 2026 results. This morning's presentation will include remarks from Steve Basta, our president and CEO, and Sanjeev Narula, our chief financial and business officer. Before we begin, let me remind you that we will be making a number of forward-looking statements throughout today's presentation. These forward-looking statements involve risks and uncertainties, many of which are beyond Phathom's control. Actual results may materially differ from the forward-looking statements, and any such risks may materially adversely affect our business and result of operations and the trading prices for Phathom's common stock. Discussion of these statements and risk factors is available on the current safe harbor slide, as well as in the Risk Factors section of our most recent Form 10-K, today's 10-Q, and subsequent SEC filings. All forward-looking statements made on this call are based on the beliefs of Phathom as of this date, and Phathom disclaims any obligations to update these statements. Later in the call, we will be commenting on both GAAP and non-GAAP financial measures. Specifically, in the scope of this discussion, when we refer to cash operating expenses, please note we are referring to the non-GAAP form of this measure, which excludes non-cash stock-based compensation. As always, detailed reconciliations between our non-GAAP results and the most directly comparable GAAP measures are included in this morning's press release. With that, I will now turn the call over to Steve Basta, Phathom's president and CEO, to kick us off. Steve?
Steve Basta President and CEO Thank you, Eric, and thank you, everyone, for joining our call this morning. I am pleased to share with you this morning the solid execution Phathom posted in the third quarter. Over the past year and a half, Phathom has significantly strengthened our financial position. In Q3, we delivered our second consecutive quarter of positive operating profit, excluding stock-based compensation, and once again generated positive cash flow. This quarter's net revenues grew by about 71% compared to Q3 last year and about 14% compared to last quarter. We are focused on making it easier for physicians to prescribe VOQUEZNA and for patients with GERD to get it. The physicians we talked to are already convinced of the clinical value of VOQUEZNA. In recent market research, 97% of HCPs we surveyed rated VOQUEZNA's efficacy as favorable compared to other GERD treatment options. Our job now is to make it as easy as possible for providers to prescribe VOQUEZNA for GERD and for their patients to be able to access it affordably.
Frequently Asked Questions About PHAT
When is Phathom Pharmaceuticals's next earnings date?
Phathom Pharmaceuticals's next earnings report is expected for Feb 24, 2027.
Did PHAT beat earnings estimates last quarter?
No. Phathom Pharmaceuticals reported EPS of -$0.03 for the quarter ended Sep 30, 2026, below the -$0.01 estimate by 200.00%.
What EPS do analysts expect from PHAT next quarter?
The consensus EPS estimate for Phathom Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.08 from 12 analysts, with estimates from -$0.15 to $0.07.
How often does PHAT beat earnings estimates?
Phathom Pharmaceuticals beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of -2.29%.
PHAT pages: Overview, Earnings, Forecast, Financials, Competitors